Do Externalizing and Internalizing Symptoms Moderate Medication Response in Preschool Attention-Deficit/Hyperactivity Disorder? A DBPNet Study.
Journal
Journal of developmental and behavioral pediatrics : JDBP
ISSN: 1536-7312
Titre abrégé: J Dev Behav Pediatr
Pays: United States
ID NLM: 8006933
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
27
10
2022
accepted:
08
06
2023
medline:
13
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
ppublish
Résumé
This study aimed to determine whether parent ratings of attention-deficit/hyperactivity disorder (ADHD) symptom severity or externalizing symptoms (EXT) or internalizing symptoms (INT) moderate response to stimulants (STIM) and alpha-2 adrenergic agonists (A2As) in preschool ADHD. Health records for children treated with medication for ADHD and with parent rating scale data available (N = 309; age <72 months) were reviewed at 7 Developmental-Behavioral Pediatric Research Network sites. Severity of ADHD was defined as the number of ADHD symptoms occurring often or very often on DSM-IV-based parent rating scales. EXT or INT from standardized rating scales were categorized as T score <60, 60 to <70, or ≥70. Ordinal logistic regression models predicting response to medication were calculated. The median (interquartile range) age at ADHD diagnosis was 59 (54-65) months. One hundred eighty-three participants had ADHD symptom severity, and 195 had EXT or INT data. ADHD severity was not associated with medication response. Both EXT and INT were associated with medication response but with significant medication class by EXT/INT interactions. Children with higher EXT were less likely to respond to STIM, with percentage of nonresponders for T-score categories <60, 60 to <70, and ≥70 being 3.6%, 25.7%, and 33.3% (p = 0.016) and, for A2As, being 60%, 50%, and 33.3% (p = 0.55), respectively. A similar pattern was observed for INT categories: STIM 19.4%, 22.5%, and 50.0% (p = 0.002) and A2As 42.3%, 30%, and 42.3% (p = 0.48), respectively. For preschool ADHD, low ratings of EXT or INT are associated with a high likelihood of response to STIM. By contrast, response rates to STIM and A2As are more similar for children with high levels of EXT or INT.
Identifiants
pubmed: 37696030
doi: 10.1097/DBP.0000000000001209
pii: 00004703-202309000-00001
doi:
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e447-e454Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. Children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47:199–212.
DuPaul GJ, McGoey KE, Eckert TL, et al. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry. 2001;40:508–515.
Wilens TE, Biederman J, Brown S, et al. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:262–268.
Spira EG, Fischel JE. The impact of preschool inattention, hyperactivity, and impulsivity on social and academic development: a review. J Child Psychol Psychiatry. 2005;46:755–773.
Barbaresi WJ, Campbell L, Diekroger EA, et al. The society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder: process of care algorithms. J Dev Behav Pediatr. 2020;41:S58–S74.
Wolraich ML, Hagan JF Jr, Allan C, et al. Subcommittee on children and adolescents with ADHD. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144:e20192528.
Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284–1293.
Wigal T, Greenhill L, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1294–1303.
Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.
Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry. 2007;46:1532–1572.
Black BT, Soden SE, Kearns GL, et al. Clinical and pharmacologic considerations for guanfacine use in very young children. J Child Adolesc Psychopharmacol. 2016;26:498–504.
Winders-Davis DW, Feygin Y, Creel L, et al. Epidemiology of treatment for preschoolers on Kentucky Medicaid diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2020;30:448–455.
Harstad E, Shults J, Barbaresi W, et al. α2-Adrenergic agonists or stimulants for preschool-age children with attention-deficit/hyperactivity disorder. JAMA. 2021;325:2067–2075.
Ghuman JK, Riddle MA, Vitiello B, et al. Comorbidity moderates response to methylphenidate in the preschoolers with attention-deficit/hyperactivity disorder treatment study (PATS). J Child Adolesc Psychopharmacol. 2007;17:563–580.
Wolraich ML, Lambert W, Doffing MA, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol. 2003;28:559–567.
DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford; 1998.
Achenbach T, Rescorla L. Manual for the ASEBA Preschool Forms & Profiles: An Integrated System of Multi-Informant Assessment. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2000.
Reynolds CR, Kamphaus RW. BASC-2: Behavior Assessment System for Children. 2nd ed. Circle Pines, MN: AGS Publishing; 2004.
Myers CL, Bour JL, Sidebottom KJ, et al. Same constructs, different results: examining the consistency of two behavior-rating scales with referred preschoolers. Psychol Schs. 2010;47:205–216.
Salpekar JA, Conry JA, Doss W, et al. Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder. Epilepsy Behav. 2006;9:327–334.
Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27:1–10.
Deavenport-Saman A, Vanderbilt DL, Harstad E, et al. Association of coexisting conditions, attention-deficit/hyperactivity disorder medication choice, and likelihood of improvement in preschool-age children: a developmental behavioral pediatrics research Network study. J Child Adolesc Psychopharmacol. 2022;32:328–336.
Owens EB, Hinshaw SP, Kraemer HC, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol. 2003;71:540–552.
Charach A, Mohammadzadeh F, Belanger SA, et al. Identification of preschool children with mental health problems in primary care: systematic review and meta-analysis. J Can Acad Child Adolesc Psychiatry. 2020;29:76–105.